|
1
|
Ganem D and Prince AM: Hepatitis B virus
infection-natural history and clinical consequences. N Engl J Med.
350:1118–1129. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yeo W, Chan PK, Zhong S, Ho WM, Steinberg
JL, Tam JS, Hui P, Leung NW, Zee B and Johnson PJ: Frequency of
hepatitis B virus reactivation in cancer patients undergoing
cytotoxic chemotherapy: A prospective study of 626 patients with
identification of risk factors. J Med Virol. 62:299–307. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mandala M, Fagiuoli S, Francisci D, Bruno
R, Merelli B, Pasulo L, Tondini C, Labianca R and Roila F:
Hepatitis B in immunosuppressed cancer patients: Pathogenesis,
incidence and prophylaxis. Crit Rev Oncol Hematol. 87:12–27. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yeo W and Johnson PJ: Diagnosis,
prevention and management of hepatitis B virus reactivation during
anticancer therapy. Hepatology. 43:209–220. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lin GN, Peng JW, Xiao JJ, Liu DY and Xia
ZJ: Hepatitis B virus reactivation in hepatitis B surface antigen
seropositive patients with metastatic non-small cell lung cancer
receiving cytotoxic chemotherapy: The efficacy of preemptive
lamivudine and identification of risk factors. Med Oncol.
31:1192014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liaw YF and Chu CM: Hepatitis B virus
infection. Lancet. 373:582–592. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hoofnagle JH, Doo E, Liang TJ, Fleischer R
and Lok AS: Management of hepatitis B: Summary of a clinical
research workshop. Hepatology. 45:1056–1075. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lok AS and McMahon BJ: Chronic hepatitis
B: Update 2009. Hepatology. 50:661–662. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yeo W, Chan PK, Ho WM, Zee B, Lam KC, Lei
KI, Chan AT, Mok TS, Lee JJ, Leung TW, et al: Lamivudine for the
prevention of hepatitis B virus reactivation in hepatitis B
s-antigen seropositive cancer patients undergoing cytotoxic
chemotherapy. J Clin Oncol. 22:927–934. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lau GK, Yiu HH, Fong DY, Cheng HC, Au WY,
Lai LS, Cheung M, Zhang HY, Lie A, Ngan R and Liang R: Early is
superior to deferred preemptive lamivudine therapy for hepatitis B
patients undergoing chemotherapy. Gastroenterology. 125:1742–1749.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hsu C, Hsiung CA, Su IJ, Hwang WS, Wang
MC, Lin SF, Lin TH, Hsiao HH, Young JH, Chang MC, et al: A revisit
of prophylactic lamivudine for chemotherapy-associated hepatitis B
reactivation in non-Hodgkin's lymphoma: A randomized trial.
Hepatology. 47:844–853. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Long M, Jia W, Li S, Jin L, Wu J, Rao N,
Feng H, Chen K, Deng H, Liu F, et al: A single-center, prospective
and randomized controlled study: Can the prophylactic use of
lamivudine prevent hepatitis B virus reactivation in hepatitis B
s-antigen seropositive breast cancer patients during chemotherapy?
Breast Cancer Res Treat. 127:705–712. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Huang H, Li X, Zhu J, Ye S, Zhang H, Wang
W, Wu X, Peng J, Xu B, Lin Y, et al: Entecavir vs lamivudine for
prevention of hepatitis B virus reactivation among patients with
untreated diffuse large B-cell lymphoma receiving R-CHOP
chemotherapy: A randomized clinical trial. JAMA. 312:2521–2530.
2014. View Article : Google Scholar : PubMed/NCBI
|
